![[ Visit WOCN Website ]](/img/wocn/2011am/header.gif)
A review of patients charts (n=6) was conducted with various types of wounds not responding to typical wound care. Patients with common diagnoses of Diabetes Mellitus, Hypertension, Anemia, and Respiratory Insufficiency in relation to other systemic factors affecting wound healing (Fig 1). Patients’ age ranged from 57 to 87 y/o.
Description of Past Management:
Patient A: dehisced sacral flap incision site managed with enzymatic debrider, NPWT and silver impregnated hydrofiber, air fluidized therapy surface.
Patient B: slow healing full thickness pressure ulcer to L lateral heel managed by Dakins 1/4 strength solution and NPWT, low airloss overlay surface.
Patient C: failed flap incision site to R ischial region with tunneling managed with bacteriostatic polyvinyl alcohol (PVA) sponge, low airloss overlay surface.
Patient D: full thickness wound due to IV infiltrate of unknown substance at dorsum of L hand managed by NPWT.
Patient E: surgical dehisced wound at amputation site of R foot managed by NPWT, non-weight bearing.
Patient F: full thickness pressure ulcer to dorsal aspect of L foot, managed by enzymatic debrider, NPWT.
Clinical Approach: Wounds managed with ECM in conjunction with other therapies. 66% of patients required 2 applications, 33% of patients required 4 applications of the ECM. Cover dressings include use of silver impregnated hydrofiber secured by silicone foam dressing and NPWT.
Outcomes: Average change in wound volume of -10.9. Patients’ wounds responded with healing at minimum of 7 days to maximum of 21 days. 83% of patients with healed wounds at discharge. (Figure 2, 3).
Conclusion:
Use of the extracellular matrix-porcine derived wound product as adjunct therapy in combination with other therapies indicated positive response to different types of wounds with age of wounds ranging from 9 days to 271 days. (Figure 4). Product usage provided shorter length of stay, positive healing outcomes.